Erkki Lathouwers

Final 192‐week efficacy and safety of once‐daily darunavir/ritonavir compared with lopinavir/ritonavir in <scp>HIV</scp>‐1‐infected treatment‐naïve patients in the <scp>ARTEMIS</scp> trial

Chloe Orkin, E DeJesus, Homayoon Khanlou et al. · HIV Medicine · 2012 · 158 citations · Full text

Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients

Pedro Cahn, Jan Fourie, Beatriz Grinsztejn et al. · AIDS · 2011 · 114 citations

Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial

Chloe Orkin, Jean‐Michel Molina, Eugènia Negredo et al. · The Lancet HIV · 2017 · 96 citations

Protease Inhibitors, Treatment And Prevention, Pharmacology +9

A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients

Joseph J. Eron, Chloe Orkin, Joel E. Gallant et al. · AIDS · 2018 · 85 citations · Full text

Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients

Sandra De Meyer, Erkki Lathouwers, Inge Dierynck et al. · AIDS · 2009 · 58 citations